A phase I study of TAS-109 given by 14-day continuous central intravenous infusion in patients with advanced solid tumors (TAS109-0401)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2009
At a glance
- Drugs TAS 109 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 21 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
- 02 Aug 2006 New trial record.